难治性肺癌中国专家共识  

Chinese expert consensus on refractory lung cancer

作　　者：中华医学会呼吸病学分会 胡成平[2] 陈良安[3] Chinese Thoracic Society

机构地区：[1]不详 [2]中南大学湘雅医院,长沙410000 [3]解放军总医院第一医学中心,北京100853

出　　处：《中华结核和呼吸杂志》2024年第4期301-312,共12页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家重大疾病(肺癌)多学科合作诊疗能力建设项目(z027002)。

摘　　要：肺癌在我国的发病率及病死率均居恶性肿瘤之首,严重危害人民的生命健康。难治性肺癌指对标准治疗反应低,或尚无标准治疗,缺乏高效低毒治疗方案的肺癌。目前对于难治性肺癌尚缺乏明确定义及治疗相关共识。为了更好地指导临床合理、安全、有效地治疗难治性肺癌,中华医学会呼吸病学分会肺癌学组的专家,针对我国肺癌实际诊疗情况,参考了国内外最新研究数据、相关指南共识及专家临床实践经验,制定了本共识。共识围绕难治性SCLC、难治性驱动基因阳性NSCLC、难治性驱动基因阴性NSCLC、精准诊疗新技术方案等四个方面分别给出推荐意见,为我国医师提供难治性肺癌的用药建议和参考。The incidence and mortality of lung cancer in China are the highest of all malignant tumors,seriously endangering people′s lives and health.Refractory lung cancer is lung cancer that is unresponsive to standard treatment and is difficult to treat,or lung cancer for which a standard treatment has not yet been defined.However,there is still a lack of clear definition and consensus on the treatment of refractory lung cancer.In order to provide guidance for the clinically effective and safe treatment of refractory lung cancer,experts from Chinese Thoracic Society Lung Cancer Study Group have formulated this consensus,on the basis of the actual situation in the field of diagnosis and treatment in our country,with reference to the latest research data,relevant guidelines at home and abroad and experts′clinical practice experience.The consensus makes recommendations on the application of four aspects:refractory small cell lung cancer(SCLC),refractory driver gene-positive non-small cell lung cancer(NSCLC),refractory driver gene-negative NSCLC,and new technological solutions for precision diagnosis and treatment.It also provides references for Chinese clinicians on the use of drugs for refractory lung cancer.

关 键 词：肺肿瘤 治疗 专家共识 

分 类 号：R734.2[医药卫生—肿瘤]